Track Vaxcyte, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Vaxcyte, Inc. PCVX · Stock Open Vaxcyte, Inc. in new tab

63.37 USD
EPS
-8.05
P/B
3.93
ROE
-42.68
Beta
1.29
Target Price
116.40 USD
Loading chart...
Key Metrics
Earnings dateFeb. 23, 2027
EPS-8.05
Book Value16.67
Price to Book3.93
Debt/Equity8.91
% Insiders0.468%
Estimates
Forward P/E-9.90
Forward EPS-6.62
Target Mean Price116.40

DCF valuation

Model fair value for Vaxcyte, Inc. (PCVX)
Result
Sign in to run the valuation for PCVX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
10 analysts · consensus Strong buy · mean target 116.40 USD (low 75.00, high 163.00) · as of 12 Nov 2026
Low 75.00
Mean 116.40
High 163.00
Price 63.37
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Vaxcyte, Inc. Logo Vaxcyte, Inc. Analysis (PCVX)

United States Health Care Official Website Stock

Is Vaxcyte, Inc. a good investment? Vaxcyte, Inc. (PCVX) is currently trading at 63.37 USD. Market analysts have a consensus price target of 116.40 USD. This suggests a potential upside from current levels.

Earnings Schedule: Vaxcyte, Inc. is expected to release its next earnings report on Feb. 23, 2027. The market consensus estimate for Forward EPS is -6.62.

Investor FAQ

Does Vaxcyte, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Vaxcyte, Inc.?

Vaxcyte, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 23, 2027. The company currently has a trailing EPS of -8.05.

Company Profile

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Exchange Ticker
FRA (Germany) 5VA.F
STU (Germany) US92243G1085.SG
NMS (United States) PCVX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion